Immunogenicity and efficacy of Zika virus Envelope Domain III in DNA, protein and ChAdOx1 adenoviral-vectored vaccines

López-Camacho, C. et al. (2020) Immunogenicity and efficacy of Zika virus Envelope Domain III in DNA, protein and ChAdOx1 adenoviral-vectored vaccines. Vaccines, 8(2), 307. (doi: 10.3390/vaccines8020307) (PMID:32560145)

217948.pdf - Published Version
Available under License Creative Commons Attribution.



The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV infection, using several vaccine platforms that present the antigen in various ways. We provide data demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice but also provided limited protection against ZIKV in two physiologically different mouse challenge models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like the dengue virus, which has close similarities with ZIKV-EDIII, this antigen might not be a suitable vaccine candidate for the correct induction of protective immune responses against ZIKV.

Item Type:Articles
Additional Information:This report is independent research funded by the UK Department of Health and Social Care through Innovate UK “New vaccines for global epidemics: development and manufacture” grant No. 972216 (ARS), and also funded from an ODA budget (Global Health (ODA), 16/107/05 - Design, development and GMP manufacture of a Zika vaccine) (AHP, ARS). The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care. ARS is a Jenner Investigator and an Oxford Martin Fellow. AP is supported by the UK Medical Research Council. JM is supported by an MRC-Newton Fund grant, GRS is aWellcome Trust Senior Investigator.
Glasgow Author(s) Enlighten ID:De Lorenzo, Dr Giuditta and Patel, Professor Arvind
Creator Roles:
De Lorenzo, G.Conceptualization, Data curation, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing
Patel, A.Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing
Authors: López-Camacho, C., De Lorenzo, G., Slon-Campos, J. L., Dowall, S., Abbink, P., Larocca, R. A., Kim, Y. C., Poggianella, M., Graham, V., Findlay-Wilson, S., Rayner, E., Carmichael, J., Dejnirattisai, W., Boyd, M., Hewson, R., Mongkolsapaya, J., Screaton, G. R., Barouch, D. H., Burrone, O. R., Patel, A. H., and Reyes-Sandoval, A.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Vaccines
ISSN (Online):2076-393X
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Vaccines 8(2):307
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
173566Design, development and GMP manufacture of a Zika vaccineArvind PatelDepartment of Health and Social Security (DHEALTH)16/107/05III-MRC-GU Centre for Virus Research